To determine whether selective uptake of HA-CPNs by CD44 + glioma populations can impact their proliferative potential CD44-, CD44 + and heterogeneous populations of U-251 cells were treated with HA-CPNs for 7 days and sorted based on the HA-CPN content and proliferation was monitored over 7 days. This evidence concerns the gene CD44 and glioma.